Curasight (CURAS) Investor update summary

Capital raise and use of proceeds

• Rights issue aims to raise up to DKK 100 million, with about 47% already secured through investor and management commitments, including Curium, Pentwater, and other guarantors.

• Existing shareholders can subscribe for new shares at DKK 1.98 each, with the subscription period from May 2 to May 16, 2025.

• Proceeds will extend the cash runway to the second half of 2026 and support strategic flexibility for partnerships.

• Funds will finance a phase 1 trial for U-Treat in brain cancer and completion of a phase 2 U-Trace study in prostate cancer, with key data readouts expected in H2 2025 and H1 2026.

• Additional working capital will support ongoing operations and first patient inclusion in U-Treat phase 2 for brain cancer in H1 2026.

Clinical development and milestones

• U-Treat phase 1 brain cancer study expects first patient dosing in September, with preliminary data by end of 2025 and final data in H1 2026.

• U-Trace phase 2 prostate cancer study is progressing, with 19 of 27 patients enrolled in part 1 and expansion to nine centers planned for part 2.

• Both studies are designed to generate data that could drive new partnerships and commercial opportunities.

• Key milestones in 2025 include regulatory approvals, trial initiations, and preliminary efficacy data for both U-Trace and U-Treat platforms.

• Clinical trials are planned or underway in glioblastoma, prostate, lung, head & neck, and neuroendocrine tumors.

Product pipeline and market potential

• U-Treat targets a €5.1 billion annual market in brain cancer, with high unmet need and strong preclinical efficacy data.

• U-Trace aims to replace invasive biopsies with PET imaging, addressing a large prostate cancer market with over 500,000 new cases annually and a EUR 1 billion market potential.

• U-Trace imaging market potential is estimated at EUR 195 million annually.